Press Releases News Category CompanyFinancialGeneralProductScience Year None202320222021 Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD. Sep 14, 2023 Read More Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S. Aug 29, 2023 Read More Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers Aug 10, 2023 Read More Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis. Aug 09, 2023 Read More Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day Aug 01, 2023 Read More Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges Jul 11, 2023 Read More Ocean Biomedical, Inc. Joins the Russell 2000® Index Jun 27, 2023 Read More Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma. Jun 26, 2023 Read More Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe Jun 23, 2023 Read More Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing Jun 21, 2023 Read More First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page » Displaying 11 - 20 of 57
Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD. Sep 14, 2023 Read More
Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S. Aug 29, 2023 Read More
Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers Aug 10, 2023 Read More
Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis. Aug 09, 2023 Read More
Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day Aug 01, 2023 Read More
Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges Jul 11, 2023 Read More
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma. Jun 26, 2023 Read More
Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe Jun 23, 2023 Read More
Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing Jun 21, 2023 Read More
